FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1918896377> ?p ?o ?g. }

• W1918896377 endingPage "122" @default.
• W1918896377 startingPage "115" @default.
• W1918896377 abstract "The elderly population is susceptible to haematological malignancies, and these elderly patients are intolerant to cytotoxic drugs. Therefore, the exploration of a safe and reliable strategy exclusive of chemotherapy is critical in improving the prognosis of elderly patients with haematological malignancies. We evaluated the safety and the efficacy of autologous cytokine-induced killer (CIK) cells combined with recombinant human interleukin 2 (rhIL-2) in the treatment of haematological malignancies in elderly patients. Peripheral blood mononuclear cells were isolated from 20 elderly patients with haematological malignancies, then augmented by priming with interferon gamma, rhIL-2 and CD3 monoclonal antibody. The autologous CIK cells (2-3 × 10(9)) were transfused back to patients, followed by a subcutaneous injection of IL-2 (1 mU/day) for 10 consecutive days. The regimen was repeated every 4 weeks. The host cellular immune function, tumour-related biological parameters, imaging characteristics, disease condition, quality of life and survival time were assessed. Fourteen patients received 8 cycles of transfusion and 6 received 4 cycles. No adverse effects were observed. The percentages of CD3(+), CD3(+) CD8(+) and CD3(+) CD56(+) cells were significantly increased (p < 0.05), and the levels of serum β2 microglobulin and lactate dehydrogenase (LDH) were markedly decreased (p < 0.05) after autologous CIK cell transfusion. Cancer-related symptoms were profoundly alleviated, as demonstrated by the improved quality of life (p < 0.01). Complete remission was observed in 11 patients, persistent partial remission in 7 patients and stable disease in 2 patients. At the end of follow-up, the mean survival time was 20 months. Transfusion with autologous CIK cells plus rhIL-2 treatment is safe and effective for treating haematological malignancies in elderly patients." @default.
• W1918896377 created "2016-06-24" @default.
• W1918896377 creator A5003349024 @default.
• W1918896377 creator A5013752846 @default.
• W1918896377 creator A5023261296 @default.
• W1918896377 creator A5023363049 @default.
• W1918896377 creator A5028366101 @default.
• W1918896377 creator A5042023245 @default.
• W1918896377 creator A5057303943 @default.
• W1918896377 creator A5067287490 @default.
• W1918896377 creator A5067754534 @default.
• W1918896377 creator A5075012194 @default.
• W1918896377 date "2011-08-23" @default.
• W1918896377 modified "2023-10-05" @default.
• W1918896377 title "Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial" @default.
• W1918896377 cites W1481357784 @default.
• W1918896377 cites W1568889871 @default.
• W1918896377 cites W187238933 @default.
• W1918896377 cites W1912693401 @default.
• W1918896377 cites W1971012938 @default.
• W1918896377 cites W1981132053 @default.
• W1918896377 cites W1994388961 @default.
• W1918896377 cites W2002807798 @default.
• W1918896377 cites W2005796830 @default.
• W1918896377 cites W2008889355 @default.
• W1918896377 cites W2010736776 @default.
• W1918896377 cites W2021595472 @default.
• W1918896377 cites W2037329643 @default.
• W1918896377 cites W2040900427 @default.
• W1918896377 cites W2058015212 @default.
• W1918896377 cites W2066773018 @default.
• W1918896377 cites W2074217324 @default.
• W1918896377 cites W2081335687 @default.
• W1918896377 cites W2091283140 @default.
• W1918896377 cites W2146016420 @default.
• W1918896377 cites W2147548158 @default.
• W1918896377 cites W2148752139 @default.
• W1918896377 cites W2298663470 @default.
• W1918896377 cites W2300937173 @default.
• W1918896377 cites W4321835902 @default.
• W1918896377 doi "https://doi.org/10.1002/hon.1012" @default.
• W1918896377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22972689" @default.
• W1918896377 hasPublicationYear "2011" @default.
• W1918896377 type Work @default.
• W1918896377 sameAs 1918896377 @default.
• W1918896377 citedByCount "26" @default.
• W1918896377 countsByYear W19188963772013 @default.
• W1918896377 countsByYear W19188963772014 @default.
• W1918896377 countsByYear W19188963772015 @default.
• W1918896377 countsByYear W19188963772016 @default.
• W1918896377 countsByYear W19188963772017 @default.
• W1918896377 countsByYear W19188963772018 @default.
• W1918896377 countsByYear W19188963772020 @default.
• W1918896377 countsByYear W19188963772021 @default.
• W1918896377 countsByYear W19188963772022 @default.
• W1918896377 crossrefType "journal-article" @default.
• W1918896377 hasAuthorship W1918896377A5003349024 @default.
• W1918896377 hasAuthorship W1918896377A5013752846 @default.
• W1918896377 hasAuthorship W1918896377A5023261296 @default.
• W1918896377 hasAuthorship W1918896377A5023363049 @default.
• W1918896377 hasAuthorship W1918896377A5028366101 @default.
• W1918896377 hasAuthorship W1918896377A5042023245 @default.
• W1918896377 hasAuthorship W1918896377A5057303943 @default.
• W1918896377 hasAuthorship W1918896377A5067287490 @default.
• W1918896377 hasAuthorship W1918896377A5067754534 @default.
• W1918896377 hasAuthorship W1918896377A5075012194 @default.
• W1918896377 hasConcept C114684123 @default.
• W1918896377 hasConcept C126322002 @default.
• W1918896377 hasConcept C167672396 @default.
• W1918896377 hasConcept C181199279 @default.
• W1918896377 hasConcept C185592680 @default.
• W1918896377 hasConcept C197934379 @default.
• W1918896377 hasConcept C203014093 @default.
• W1918896377 hasConcept C2777318727 @default.
• W1918896377 hasConcept C2777371288 @default.
• W1918896377 hasConcept C2778690821 @default.
• W1918896377 hasConcept C2779109515 @default.
• W1918896377 hasConcept C55493867 @default.
• W1918896377 hasConcept C71924100 @default.
• W1918896377 hasConcept C8891405 @default.
• W1918896377 hasConcept C90924648 @default.
• W1918896377 hasConceptScore W1918896377C114684123 @default.
• W1918896377 hasConceptScore W1918896377C126322002 @default.
• W1918896377 hasConceptScore W1918896377C167672396 @default.
• W1918896377 hasConceptScore W1918896377C181199279 @default.
• W1918896377 hasConceptScore W1918896377C185592680 @default.
• W1918896377 hasConceptScore W1918896377C197934379 @default.
• W1918896377 hasConceptScore W1918896377C203014093 @default.
• W1918896377 hasConceptScore W1918896377C2777318727 @default.
• W1918896377 hasConceptScore W1918896377C2777371288 @default.
• W1918896377 hasConceptScore W1918896377C2778690821 @default.
• W1918896377 hasConceptScore W1918896377C2779109515 @default.
• W1918896377 hasConceptScore W1918896377C55493867 @default.
• W1918896377 hasConceptScore W1918896377C71924100 @default.
• W1918896377 hasConceptScore W1918896377C8891405 @default.
• W1918896377 hasConceptScore W1918896377C90924648 @default.
• W1918896377 hasIssue "3" @default.
• W1918896377 hasLocation W19188963771 @default.

• next